Long-term naltrexone treatment modifies luteinizing hormone secretory amplitude in polycistic ovary syndrome

R. E. Nappi, F. Petraglia, A. Bacchi-Modena, L. Benassi, A. D. Genazzani, G. Comitini, C. Nappi, A. R. Genazzani

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the neuroendocrine effect of naltrexone in the long-term treatment of polycystic ovary syndrome. Methods: The chronobiological secretory characteristics of the pituitary hormones FSH, LH, PRL, and cortisol were investigated over a period of 8 hours in a group of polycystic ovary syndrome patients before and after treatment with naltrexone (50 mg per os daily for 28 days). Results: No significant changes in integrated LH mean values and mean LH pulse frequency were found, whereas the mean LH pulse amplitude was significantly lower (p

Original languageEnglish
Pages (from-to)64-68
Number of pages5
JournalItalian Journal of Gynaecology and Obstetrics
Volume5
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Long-term naltrexone treatment modifies luteinizing hormone secretory amplitude in polycistic ovary syndrome'. Together they form a unique fingerprint.

  • Cite this

    Nappi, R. E., Petraglia, F., Bacchi-Modena, A., Benassi, L., Genazzani, A. D., Comitini, G., Nappi, C., & Genazzani, A. R. (1993). Long-term naltrexone treatment modifies luteinizing hormone secretory amplitude in polycistic ovary syndrome. Italian Journal of Gynaecology and Obstetrics, 5(2), 64-68.